Kenvue Inc (KVUE)

Currency in USD
17.58
-0.03(-0.17%)
Closed·
17.580.00(0.00%)
·
High dividend Yield
KVUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.5217.71
52 wk Range
14.0225.17
Key Statistics
Prev. Close
17.61
Open
17.56
Day's Range
17.52-17.71
52 wk Range
14.02-25.17
Volume
13.78M
Average Volume (3m)
35.62M
1-Year Change
-24.9252%
Book Value / Share
5.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KVUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.58
Upside
+11.40%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Kenvue Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Kenvue Inc SWOT Analysis


Strategic Overhaul
Explore Kenvue's ambitious "Extraordinary Powers" strategy, aimed at simplifying operations and driving innovation across its diverse product portfolio
Market Challenges
Delve into Kenvue's response to declining organic sales and regulatory scrutiny, including leadership changes and a comprehensive strategic review
Brand Powe
Learn how Kenvue leverages its iconic brands like Tylenol and Neutrogena to maintain market leadership despite fierce competition in the consumer health secto
Financial Outlook
Analyst price targets range from $22 to $29, reflecting varied perspectives on Kenvue's potential for operational improvements and long-term value creation
Read full SWOT analysis

Kenvue Inc Earnings Call Summary for Q2/2025

  • Q2 2025 adjusted EPS of $0.29 missed expectations by 17.14%, revenue of $3.84B fell short by 8.13%
  • Stock rose 1.45% pre-market despite earnings miss; organic sales declined 4.2% in Q2
  • Full-year 2025 guidance: organic sales to decline low single digits, adjusted EPS projected at $1.00-$1.05
  • Company focusing on largest brands, innovation, and operational efficiency amid cautious consumer sentiment
  • Considering strategic alternatives to streamline operations; 83% of U.S. business holding or gaining market share
Last Updated: 2025-08-07, 01:12 p/m
Read Full Transcript

Compare KVUE to Peers and Sector

Metrics to compare
KVUE
Peers
Sector
Relationship
P/E Ratio
23.0x22.1x12.2x
PEG Ratio
0.56−1.550.03
Price/Book
3.1x4.0x1.5x
Price / LTM Sales
2.2x2.2x0.9x
Upside (Analyst Target)
8.1%9.3%20.5%
Fair Value Upside
Unlock18.7%11.1%Unlock

Analyst Ratings

2 Buy
11 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 19.58
(+11.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold18.00+2.39%19.00MaintainApr 15, 2026
UBS
Hold18.00+2.39%19.00MaintainApr 07, 2026
Barclays
Hold19.00+8.08%18.00MaintainMar 05, 2026
Jefferies
Hold19.00+8.08%18.00MaintainFeb 23, 2026
UBS
Hold19.00+8.08%17.00MaintainFeb 18, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.76%
Dividend Yield
4.75%
Industry Median 2.82%
Annualized payout
0.83
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 17, 2026
EPS / Forecast
0.27 / 0.33
Revenue / Forecast
3.78B / 4.11B
EPS Revisions
Last 90 days

KVUE Income Statement

People Also Watch

135.11
SATS
+1.43%
10.8800
ADMA
-1.18%
5.33
CXM
-2.20%
44.92
GDS
+0.49%

FAQ

What Is the Kenvue (KVUE) Stock Price Today?

The Kenvue stock price today is 17.58 USD.

What Stock Exchange Does Kenvue Trade On?

Kenvue is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Kenvue?

The stock symbol for Kenvue is "KVUE."

Does Kenvue Pay Dividends? What’s The Current Dividend Yield?

The Kenvue dividend yield is 4.75%.

What Is the Kenvue Market Cap?

As of today, Kenvue market cap is 33.75B USD.

What Is Kenvue's Earnings Per Share (TTM)?

The Kenvue EPS (TTM) is 0.76.

When Is the Next Kenvue Earnings Date?

Kenvue will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is KVUE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Kenvue Stock Split?

Kenvue has split 0 times.

How Many Employees Does Kenvue Have?

Kenvue has 21890 employees.

What is the current trading status of Kenvue (KVUE)?

As of Apr 21, 2026, Kenvue (KVUE) is trading at a price of 17.58 USD, with a previous close of 17.61 USD. The stock has fluctuated within a day range of 17.52 USD to 17.71 USD, while its 52-week range spans from 14.02 USD to 25.17 USD.

What Is Kenvue (KVUE) Price Target According to Analysts?

The average 12-month price target for Kenvue is 19.58 USD, with a high estimate of 23 USD and a low estimate of 18 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +11.40% Upside potential.

What Is the KVUE Premarket Price?

KVUE's last pre-market stock price is 17.52 USD. The pre-market share volume is 4,840.00, and the stock has decreased by -0.09, or -0.51%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.